Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

IVDiagnostics Opens New Lab

By Drug Discovery Trends Editor | July 26, 2012

A Northwest Indiana life-sciences company has increased its presence at the Purdue Technology Center of Northwest Indiana by establishing a new laboratory to expand research that monitors and measures cells for improved cancer treatments.

IVDiagnostics develops, tests, and markets diagnostic tools that measure and monitor cancer tumor cells. The company’s technology identifies circulating tumor cells, which are released from primary cancer tumors into the bloodstream and then lodge at distant organs to begin new cancer growth. Health-care providers use the information from IVDiagnostics to determine cancer treatment effectiveness.

“Our company supports the goals of raising the bar for molecular medicine,” said Frank Szczepanski, CEO of IVDiagnostics. “Our expanded life sciences lab will enable us to provide even more detailed information for improved cancer treatments.”

Thomas Szczepanski, director of marketing and support systems at IVDiagnostics, described why the company decided to expand in Purdue Technology Center.

“The Purdue Technology Center of Northwest Indiana is ideally equipped to offer readily available space and state-of-the-art facilities for companies such as IVDiagnostics,” he said.

Frank Szczepanski also spoke about the opportunity to create a center for advanced cancer research in Northwest Indiana that can have a global impact. He is chief operating officer of The Foundation for Molecular Medicine, a group that supports research on improving the diagnosis and treatment of cancer, heart and neurodegenerative diseases.

“We strongly feel that teaching more biotechnology courses in Northwest Indiana, having regional hospitals put advanced molecular diagnostics and treatment options into practice, and doing more research collaboration between clinicians and biotech firms will be a driving force for collaboration among universities, hospitals, students and professors to learn and put into practice non-toxic molecular diagnosis and treatment alternatives,” he said. “Together, with other biotech companies at both the Purdue Technology Center of Northwest Indiana and throughout the Midwest, we can make this happen.”

Date: July 26, 2012
Source: Purdue Research Park


Filed Under: Drug Discovery

 

Related Articles Read More >

Roche in Drug Discovery & Development Pharma 50
Roche’s bispecific antibody Lunsumio wins priority review from FDA for non-Hodgkin lymphoma
Tiffany Hurd
CB Therapeutics biz dev lead sees upside for psychedelics in mental health and beyond
Pharmacovigilance
A new era of pharmacovigilance: Worldwide master key for drug safety monitoring
Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50